| Literature DB >> 24589438 |
Abstract
N-myc (MYCN), a member of the Myc family of basic-helix-loop-helix-zipper (bHLHZ) transcription factors, is a central regulator of many vital cellular processes. As such, N-myc is well recognized for its classic oncogenic activity and association with human neuroblastoma. Amplification and overexpression of N-myc has been described in other tumor types, particularly those of neural origin and neuroendocrine tumors. This review outlines N-myc's contribution to normal development and oncogenic progression. In addition, it highlights relevant transcriptional targets and mechanisms of regulation. Finally, the clinical implications of N-Myc as a biomarker and potential as a target using novel therapeutic approaches are discussed. ©2014 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24589438 DOI: 10.1158/1541-7786.MCR-13-0536
Source DB: PubMed Journal: Mol Cancer Res ISSN: 1541-7786 Impact factor: 5.852